Attendee search 

Cro

An international enterprise dedicated to the innovation, ptoduce and selling of innovative drugs

Illumina is a provider of Next Generation Sequencing technology

healthcare investment

大博医疗科技股份有限公司是一家A股上市的综合性医用高值耗材公司。立足于骨科产品的行业优势地位，现已是国内最具成长性的医用高值耗材企业之一。

Mabwell, founded in 2017 in Zhangjiang District of Shanghai, is an innovation-based bio-pharmaceutical company with 9 biomedical R&D and manufacturing subsidiaries and a strong, diverse and experienced technical team under its wing. With its world class high-throughput antibody drug discovery platform, well-established pharmaceutical research system and mature process development, the company is dedicated to the R&D and manufacturing of therapeutic monoclonal antibodies, long acting recombinant protein and other new macromolecular drugs. Currently, 30 different drugs for tumor, autoimmunity, infection resistance and ophthalmology are being developed at various stages, among which 1 is cleared for production and 6 are in clinical research with 4 in key clinical stage. Guided by an innovation-driven strategy, the company has actively pushed for commercialization with a production facility built in line with both Chinese and Western GMP standards already up and running in Taizhou, Jiangsu province. Another large-scale industrial base in Shanghai is under construction. The first drug variety will be on the market in 2020 and the number will go up to 4 (or more) in 2023, Mabwell closed series A financing of 1.97 Billion Yuan at April, 2020, demonstrating the company’s ambition to become a leading bio-pharmaceutical enterprise in China.

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.

Medprin focuses on RD and sales and marketing of implantable medical devices with products in general surgery and neurosurgery. Current Medprin is actively looking for promising startups /team with matching technology/products that Medprin can both invests financially and develops long term partnership.

CTS Capital was founded in 2017. As a private equity firm, CTS Capital focuses on investment opportunities in the biotechnology and healthcare services industries. CTS Capital is managed by a team of professionals with deep industry knowledge, extensive experiences in private equity and global strategic insights. Driven by our team’s business acumen and investment expertise, CTS Capital has made investments in companies at the cutting edge of the biotechnology and healthcare industries, including innovative drugs, medical devices, diagnostics, gene technology, digital health and AI in healthcare，etc.
We employ a research-driven investment approach and collaborate closely with our companies to build lasting and impactful businesses in the life sciences and healthcare industries. We are committed to working in close partnership with the top innovative pharmaceutical, biotech and medical technology companies to promote biotechnology innovation and healthcare transformation in China.